Abstract 5658
Background
A convenient and accurate method to improve the effectiveness of colorectal-cancer screening is still under exploration. This may be achieved by a diagnostic model based on 5-hydroxymethylcytosine (5-hmC).
Methods
We collected peripheral venous blood from 285 colorectal cancer patients and 285 healthy people at Zhongshan Hospital, Shanghai. The 5-hmC level of each gene locus in circulating-free DNA (cfDNA) was detected using a highly sensitive sequencing method. Of 285 subjects, 178 in each group were randomly selected as training set. The first 100 gene loci with the most significant difference of 5-hmC level were selected for establishing a diagnostic model (Logistic regression model) based on machine-learning method. The rest subjects in each group were used as validating set to validate this model. Further, we analysed the influence of several clinicopathological factors on 5-hmC level.
Results
In training set, the comprison of the 5-hmC level suggested that the expression of 5-hmC in cfDNA was significantly different between the two groups. Of the 100 gene loci, 35 were included in the model. In internal validation, the sensitivity and specificity of the model were 88.8% and 89.9%, respectively. While the sensitivity and specificity 81.3% and 89.7%, respectively, in external validation using the validating set. The area under ROC curve of external validation was 0.946. For colorectal cancer stages I-IV, the diagnostic sensitivities were 78.7%, 81.9%, 88.2% and 95.6%, respectively. We also found that age, gender, Ras status or the site of primary tumor had no significant effect on the expression of 5-hmC. However, there was a statistically difference of 5-hmC level between stage I-III and stage IV.
Conclusions
Our study identified the gene loci with significantly different 5-hmC level between colorectal cancer patients and healthy people, then we established a diagnostic model of colorectal cancer with high sensitivity and specificity. However, the utility of the model still need further verification in large-scale screening experiments.
Clinical trial identification
NCT03599947 09/16/2018.
Editorial acknowledgement
Shanghai Yibien Gene Technology Co., Ltd. Provides Testing Platform.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract